AstraZeneca drug prices evolving in response to Trump policy, executive says

AZN•2026-07-27

Pricing strategy for new launches

AstraZeneca has been adjusting its pricing strategy for new drug launches in response to U.S. President Donald Trump's "most-favoured-nation" policy seeking lower drug prices for Americans, a senior company executive said on Monday.

"Our pricing approach across all of launches now has really evolved in response to MFN," David Fredrickson, AstraZeneca's executive vice president for the oncology business, told investors.

AstraZeneca drug prices evolving in response to Trump policy, executive says

Pricing strategy for new launches

Related News

Strategy repurchases USD 25 million of STRC preferred shares under buyback program

Cracker Barrel names ex-Bloomin' Brands CEO David Deno as CEO, effective Aug. 10, 2026

Oil prices near one-week low after US, Iran pause fighting over weekend

SEGG Media shifts Lottery.com to affiliate-only model, names it global master platform

Kazakhstan's daily oil output halves after export terminal closure, source says